ASAM's 44th Annual Medical-Scientific Conference gives you access to the largest gathering of physicians, nurses, psychologists and counselors dedicated to the treatment of education, research and prevention of addictions.

Our 2013 meeting will draw over 1,000 physicians, researchers and other health professionals for a packed program of clinical and scientific sessions on addiction medicine. Many social events, including the Welcome and Networking Reception, and refreshment breaks will be held in the Exhibit Hall to draw in attendees. These events, combined with Poster Sessions in the Exhibit Hall, will offer great opportunities for attendees and exhibitors to interact and for you to develop new contacts.

• Tuesday, April 23, 2013

   

  3:00 pm – 5:00 pm	Finance Committee Meeting
  6:00 pm – 9:00 pm	Board of Directors Meeting

  Back to top

• Wednesday, April 24, 2013

  8:00 am – 6:00 pm	Board of Directors Meeting
  5:00 pm – 8:00 pm	Registration Open
  10:00 pm – 11:00 pm	Mutual Help Meeting

  Back to top

• Thursday, April 25, 2013

  7:00 am – 8:00 am	Mutual Help Meeting Held each morning and evening of the conference, these peer-run addiction problem-specific support group meetings are open to any participant.
  7:00 am – 8:00 pm	Registration Open
  8:00 am – 5:30 pm	Ruth Fox Course for Physicians (Separate Registration Fee)  Pain & Addiction Course (Separate Registration Fee)
  5:00 pm – 6:00 pm	New Member Welcome Reception
  5:00 pm – 6:00 pm	Ruth Fox Endowment Scholarship Meeting
  6:00 pm – 8:00 pm	Welcome Reception in the Exhibit Hall  - Exhibit Hall Open Join friends and colleagues for the gala grand opening of ASAM’s 44th Annual Medical-Scientific Conference Exhibit Hall. Tour nearly one hundred exhibits and the largest collection of poster presentations assembled to date. The Exhibit Hall is the vibrant hub of networking activity throughout the conference. Visit the ASAM booth and discover a world of resources, publications and ASAM merchandise.
  8:00 pm – 10:00 pm	Component Session 1  Update on the ASAM Criteria: The Revision and Software  David Mee-Lee, MD; David Gastfriend, MD; Paul Earley, MD FASAM; George Kolodner, MD; Marc Fishman, MD, FASAM  Component Session 2  Addressing Substance Use Disorders in Primary Care: How Can We Improve?   Norm Wetterau, MD, FASAM; Paul Seale, MD; Abdel Fahmy, MD  Component Session 3  Maintenance of Certification in Addiction Medicine: What it Means for You, and How to Use Your Computer and the ABAM Diplomate Web Portal to Meet Maintenance of Certification Program Requirements  Gavin Bart, MD, FACP, FASAM; Bob Sokol, MD; Lia Bennett, MPH; Margaret Jarvis, MD, FASAM  Component Session 4  Influencing Health Policy: ASAM Advocacy in 2013  Alexis Horan, MPP, Kelly Clark, MD, MBA, FASAM  Component Session 5 Patient Access to Medication Assisted Treatment: Responding to State Access Limitations  Richard Soper, MD, JD, MS, FASAM, DABAM; Mark Kraus, MD, FASAM; Mark Publicker, MD, FASAM
  10:00 pm – 11:00 pm	Mutual Help Meeting

  Back to top

• Friday, April 26, 2013

  7:00 am – 8:00 am	Mutual Help Meeting
  7:00 am – 6:00 pm	Registration Open
  7:00 am – 8:30 am	ASAM Members Annual Business Meeting and Breakfast (ASAM Members Only – Breakfast service will start at 7:15am)  Begin the first full conference day with breakfast and an update on ASAM activities. Be sure to join ASAM’s leadership to discover the organization’s plans for the future, help set policy and celebrate the year’s accomplishments.
  8:30 am – 10:00 am	Opening Scientific Plenary & R. Brinkley Smithers Distinguished Scientist Award and Lecture  “Symmetry and Asymmetry in Addiction Medicine: The Balance Between You, Your Patient, and Your Setting”  Joseph Westermeyer, MD, MPH, PhD ASAM will honor Joseph Westermeyer, MD, PhD, MPH--this year’s recipient of the R. Brinkley Smithers Distinguished Scien – no sytist Award. Dr. Westermeyer is being recognized for his continuing support of ASAM and his crucial role in guiding alcohol research in America.  Following presentation of the Award, Dr. Westermeyer will deliver his lecture, “Symmetry and Asymmetry in Addiction Medicine: The Balance Between You, Your Patient, and Your Setting,” in which he will argue that symmetry in clinician-patient and clinician-funder interactions supports patients’ recoveries, while keeping the physician safe and sane. Asymmetric interactions, on the other hand, undermine relationships, can damage or impede recovery, and confuse or disturb the clinician. Beginning with the concepts originated by Martin Buber, Eric Berne, and E. Morton Jellinek, Dr. Westermeyer will explore methods for (1) recognizing symmetry and asymmetry in the care of addicted patients and (2) tactics and strategies for changing asymmetric relations to symmetry.    He will also discuss the experience of symmetric or asymmetric relationships with those who hire or fund us. Most common types of asymmetry are readily recognized. However, large third-party funders have begun displacing clinician-driven care (e.g., guided by the ASAM Criteria). Although these programmatic changes are often simple, well meaning, and based in one or another theory, their outcomes are often complex and unpredictable.    Finally, Dr. Westermeyer will underscore the inherent link in the symmetry with the patient and the symmetry with the funder. If these two relationships with the clinician do not coalesce, asymmetry defeats therapeutic goals and drains morale. When they coalesce, symmetry - like wind against sail - enhances therapy and supports the patient’s recovery.     As Professor of Psychiatry and Adjunct Professor of Anthropology at the University of Minnesota in Minneapolis, Dr. Westermeyer is also a staff psychiatrist and Medical Director of the Addictive Disorders Service at the Minneapolis VA Medical Center.      He earned his Doctor of Medicine degree from the University of Minnesota. Following his general practice residency, he completed a residency in psychiatry and returned to the University of Minnesota, where he earned a Master of Public Health degree and a Doctor of Philosophy degree in Psychiatry and Anthropology. He is board certified in family practice and psychiatry, with added qualification in addiction psychiatry.     In addition to his clinical practice at the Minneapolis VA Hospital, Dr. Westermeyer maintains an active research program, focusing on cross-cultural mental health issues. He has published over 100 articles, and he currently is on the editorial boards of several journals, including the American Journal of Drug and Alcohol Abuse, American Indian Alaska Native Mental Health Research, and World Cultural Psychiatry Research Review.     Celebrate the achievements of Dr. Joseph Westermeyer and be inspired by his thought-provoking lecture!
  10:00 am – 6:00 pm	Exhibit Hall Open
  10:00 am – 10:30 am	Refreshment Break in the Exhibit Hall
  10:30 am – 12:30 pm	Symposium 1 – Part I Buprenorphine: New Formulations, Medication Combinations, Indications and Longitudinal Effects Sponsored by: National Institute on Drug Abuse (NIDA) Organizer: Jag Khalsa, PhD, MS Jag Khalsa, PhD, MS; Geetha Subramaniam, MD; Gavin Bart, MD, FACP, FASAM; Roger Weiss, MD; Andrew Saxon, MD; Larissa Mooney, MD; Ryan Turncliff, PhD, Alkermes; Fredrik Tiberg, PhD, Camurus; Katherine L. Beebe, PhD, Titan Pharmaceuticals; Elliot Ehrich, MD, Alkermes The 2011 National Survey on Drug Use and Health (NSDUH) reported that 1.8 million US adults were dependent on prescription pain relievers and nearly half-a-million were heroin dependent. These addictions, associated with significant morbidity and mortality, incur both direct and indirect costs to the nation, including costs from overdose, concurrent HIV and Hepatitis C infections and dependence on other substances including cocaine. Despite the promising advent of buprenorphine (BUP) in 2002, with the unique opportunity to treat opioid dependent patients in doctors’ offices, adoption of buprenorphine in clinical practice remains low and treatment outcomes have been impacted by poor medication adherence. This day-long, two-part symposium will provide an overview of the recent advances in BUP research, including development of new formulations to improve medication adherence, e.g., BUP depot injection, probuphine implants; and testing a combination of BUP/ALKS 33 for the treatment of cocaine dependence and depression. In addition, presenters will share new findings from NIDA CTN buprenorphine trials such as predictors of outcome of the Prescription Opioid Addiction Treatment study (POATS) and the role of psychiatric comorbidity. Following the lunch break more research findings will be discussed followed by a lively panel discussion moderated by the chairs.
  10:30 am – 12:30 pm	Symposium 2                                  Clinical Quality Measures for Addiction Medicine Michael Miller, MD, FASAM, FAPA; H. Westley Clark, MD, JD, MPH, CAS, FASAM; Margaret Jarvis, MD, FASAM; Constance M. Weisner, DrPH, MSW; Elinore F. McCance-Katz, MD, PhD; Margaret M. Kotz, DO, FASAM The implementation of the Affordable Care Act (ACA) will have a significant impact on the delivery of, and payment for, addiction treatment services. Under the new Act, physicians and hospitals will be paid for clinical performance and patient outcomes rather than volume of services. The law seeks to integrate addiction services with general medical care in order to enhance care coordination and improve patient outcomes. In light of these changes, ASAM recognizes the need to define the role of the addiction specialist physician in both providing direct patient care and improving systems outcomes. The Practice Improvement and Performance Measures Action Group (PIPMAG), which comprises a Steering Committee, two Expert Panels, and a Field Review Panel, has begun the work of identifying standards of care for addiction specialists and defining the domains of addiction specialist physician performance which should be measured. This Symposium will explore the increased activity around clinical quality measurement under health reform and offer attendees an overview of ASAM’s efforts to define the roles for which addiction specialist physicians could and should be held accountable in our changing health systems. Course 1 Addiction Medicine: Closing the Gap between Science and Practice Linda Richter, PhD; Kevin Kunz, MD, MPH, FASAM; Joel Bush, MD, MC; Joseph Westermeyer, MD, PhD Course 2 Combat Trauma and Addictions Larry Ashley, Ed.S Workshop 1 60/60: All of Addiction Medicine in 60 Slides and 60 Minutes Petros Levounis, MD, MA, FASAM ; Abigail Herron, DO Workshop 2 Addiction Psychiatry via Telemedicine Terry Rustin, MD, FASAM Group I - Paper Sessions Paper 1 – Gender Differences in Substance Use and Treatment Preferences in the U.S. Military Jacqueline Pflieger, PhD; Frances Barlas, PhD; Bryan Higgins, PhD; Diana Jeffery, PhD; Mark Mattiko, MA; Benedict Diniega, MD; Maureen Forsythe, MD; Kevin Klette, MD Paper 2 – Health Plans' Provision of Substance Abuse Services Under Parity and Health Reform Maureen Stewart, PhD; Dominic Hodgkin, PhD; Sharon Reif, PhD Paper 3 – Increasing Trends in Neonatal Abstinence Syndrome: What is the Cost? Kay Roussos-Ross, MD; Gary Reisfield, MD Paper 4 – Penny Wise and Pound Foolish: Data on the Financing Drug Addiction Study Michael Liepman, MD, DFAPA, FASAM; Kathleen Gross, MD Paper 5 – The Addicted Physician: Treatment Outcome and Risk Factors Correlating to Relapse Anjali Gupta, MD; Stephanie Bologeorges, MD; Evan Goulding, MD, PhD; Daniel Angres, MD
  12:30 pm – 1:30 pm	ASAM Sponsored Complimentary Grab n’ Go Luncheon in the Exhibit Hall NEW
  12:30 pm – 2:30 pm	2013 Poster Sessions in the Exhibit Hall Poster 1 – A Novel Buprenorphine/Naloxone Tablet Formulation for the Treatment of Opioid Dependence Peter Hjelmstrom, MD, PhD; Martin Jonsson, MSc; Andreas Fischer, MSc; Cornelia Tiberg, MD; Darin Brimhall, DO, FACP; Christopher Hendy, PhD Poster 2 – Abuse of Reformulated OPANA ER: Early Findings from NAVIPPRO Data Streams Mirella Zulueta, MD; Theresa Cassidy, MD Poster 3 – Acute Pain Episode Outcomes in Patients Treated with Injectable Extended-Release Naltrexone (XR-NTX) David Gastfriend, MD; Paul Earley, MD, FASAM; Amy Turncliff, PhD; Scott Erickson, MD; Robert Woolhandler, MD Poster 4 – Associations between Anxiety Disorders and Substance Use Disorders in Substance-dependent Adolescents Alexandra Wang, BA; Maria Pagano, PhD; Michael Scur, BA; Christina Delos Reyes, MD Poster 5 – Bilateral Blindness and Paraplegia Associated with Crack Cocaine Abuse. A Case of Levamisole Associated Toxicity? Timothy Wiegand, MD, FACMT Poster 6 – Buprenorphine/Naloxone Film Diversion and Abuse Rates are Less than Tablet Formulations Eric Lavonas, MD Poster 7 – Cannabis Hyperemesis Syndrome Muhammad Sadiq, MBBS, MD Poster 8 – Case-Based Online Training to Improve Knowledge and Attitudes about Safe Opioid Prescribing Brad Tanner, MD Poster 9 - Childhood Sexual Trauma Related to Concurrent Opiate and Amphetamine Use Disorders in Adolescents Susan Wiet, MD; Lisa Ord, LCSW, PhD Poster 10 – Continuity of Clinical Efficacy with Injectable Extended-Release Naltrexone (XR-NTX) David Gastfriend, MD; Bernard Silverman, MD; Asli Memisoglu, ScD; Evgeny Krupitsky, MD, PhD; Walter Ling, MD Poster 11 – Correlating Depression to Progress through Drug Treatment Court Sara Mamman, BS, BA; Randall Brown, MD, PhD, FASAM; Michele Gassman, MA Poster 12 – Developing a Relapse Prevention Tool: Assessing Motivations for Use in Addicted Professionals Ashley Bassett, MD; Daniel Angres, MD; Stephanie Bologeorges, MD Poster 13 – Do Reductions in Drinking Wear Off? Examining Alcohol Use Patterns in an SBIRT Control Group Over 30 Months Aaron Johnson, PhD; Jason Dhabliwala, BS; Paul Seale, MD Poster 14 – Does Physical Activity Enjoyment Moderate the Relationship between Exercise and Alcohol Consumption Nadra Lisha, PhD; Adam Leventhal, PhD Poster 15 – Engaging residents in online learning Dan Vinson, MD Poster 16 – Evaluate the Effectiveness of Cognitive Behavioral Therapy and Relaxation Training on Reducing Attitude toward Tobacco Smoking Hamideh Jahangiri, MS; Alireza Norouzi, BS Poster 17 – Genetic Variations in the Mesolimbic System are Linked to Elevated Risk of Opioid Abuse Benjamin Arthur, PhD, MS, EMTM Poster 18 – Injectable Extended-Release Naltrexone in Opioid Dependence: Patients Characteristics, Coverage and Hospital Course David Gastfriend, MD; Roger Meyer, MD; William Milchak, LCSW, CAC, CCDP; Edward Bixler, PhD; David Gastfriend, MD; Doug Leslie, PhD; Jeb Bird, MD; Philip Herschman, PhD; Gerald Shulman, MA, MAC, FACATA Poster 19 – Medical Student Perceptions of Alcohol Use Among Their Peers Lisa Merlo, PhD, MPE Poster 20 – Methadone Maintenance Treatment for Opioid Dependence and QTc Interval Shannon Robinson, MD; Cassidy Zanko, MD; Abigail Goldsmith, PhD Poster 21 - Persistence and Healthcare Charges Among Opioid-Dependent Patients Treated with Buprenorphine/Naloxone Film and Tablet Formulation: Retrospective Study of a Privately Insured Database Vladimir Zah, PhD; Jane Ruby, PhD; Samuel Aballea, MS; Elizaveta Kharitonova, MS; Emilie Clay, MS Poster 22 – Predictors of Response to Naltrexone in Alcohol Dependence: A Systematic Review and Integration of the World Literature James Garbutt, MD Poster 23 – Pump It Up? Is this a Good Idea? Jamie Vizcarra, DO; Adelkola Alao, MD Poster 24 – Qualitative Evaluation of the Experience of Participants in the Dane County Operating While Intoxicated Treatment Court Randall Brown, MD, PhD, FASAM; Michele Gassman, MA Poster 25 - Recurrent Vasculitis Due to Levamisole-Adulterated Cocaine Confirmed by Laboratory Testing Rachel Gorodetsky, PharmD; Timothy Wiegand, MD, FACMT Poster 26 – Referrals to and Participation in an Ambulatory Detoxification Program from 2007 to 2011 Julie Kmiec, DO Poster 27 – Team Sports Participation in Adolescents and Alcohol and Marijuana Use Initiation Trajectories Nadra Lisha, PhD; William Crano, PhD; Kevin Delucchi, PhD Poster 28 – Unusual Case of Streptococcus Mitis Endocarditis in IV Methamphetamine User Ashwin George, MD; Svetlana Zaydman, DO Poster 29 – Use of Flumazenil in Drug Overdose JoAn Laes, MD Poster 30 – Utilization of Buprenorphine Assisted Opioid Dependence Treatment in a County Drug Court Program Michael Frost, MD Poster 31 – Video Games Among Children and Teenagers: Moroccan Avatars Imane Kendili, MD; Soumia Berrada, Professor of Psychiatry Poster 32 – How Does Sensation Seeking Relate to Exercise and Alcohol Use? Nadra Lisha, PhD; Adam Leventhal, PhD
  2:30 pm – 4:30 pm	Symposium 1 – Part II Buprenorphine: New Formulations, Medication Combinations, Indications and Longitudinal Effects Sponsored by: National Institute on Drug Abuse (NIDA) Organizer: Jag Khalsa, PhD, MS Jag Khalsa, PhD, MS; Geetha Subramaniam, MD; Gavin Bart, MD, FACP, FASAM; Frederick Tiberg, Camurus; Ryan Rurncliff, Alkermes; Katherine L. Beebe, PhD, Titan Pharmaceuticals; Elliot Ehrich, MD, Alkermes; Roger Weiss, MD; Andrew Saxon, MD; Larissa Mooney, MD Continuing the review of latest BUP research, experts will discuss liver effects and other findings from the Starting Treatment with Agonist Replacement Therapies (START) Trial; and design and methodology considerations of the Cocaine Use Reduction with Buprenorphine (CURB) study. Participants will learn of new evidence predictors of treatment, including role of psychiatric co-morbidity and additional counseling for prescription opioid dependence to guide further tailoring of BUP treatment. In addition, new findings on the longitudinal effects of BUP on liver enzymes and potential pharmacogenetic effects, to assist with monitoring the safety of and efficacy of BUP for opioid dependent patients will be explored. The session will end with a lively discussion session moderated by the chairs. Symposium 3 Treatment of Military Personnel and Their Families Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA) Organizer & Moderator: David C. Lewis, MD Rhonda Robinson Beale, MD; Mathea Falco, JD; David C. Lewis, MD; Dennis McCarty, PhD; Charles O’Brien, MD, PhD; Constance Weisner, PhD, MSW Like many sectors of society, the U.S. military has a long history of alcohol and other drug misuse and abuse. In recent years, the issue has reached crisis proportions because of skyrocketing use of opioids to treat pain and the psychological stress of multiple deployments. To better understand the problem and how it can be addressed, the Department of Defense asked the Institute of Medicine (IOM) to conduct an independent inquiry and to develop recommendations for changes in the way substance use disorders in service members and their families are prevented, identified and treated. The IOM committee delivered its report, “Substance Use Disorders in the U.S. Armed Forces,” in September 2012. The report identifies a number of barriers that limit access to addiction care—availability, gaps in insurance coverage, stigma, fear of negative consequences, and lack of confidential services—and recommends remedies for each. Members of the IOM committee will discuss their findings and the implications for addiction medicine specialists in both the military and civilian sectors. Course 3 Breastfeeding and Margaritas, Marijuana, Methadone and More Debra Bogen, MD Course 4 Combining Predictive Analytics, Outreach, Evidence Based Treatment, Case Management and Monitoring to Generate Clinical Outcome Driven Cost Reductions in High Cost Substance Dependent Populations Omar Manejwala, MD, MBA, FAPA, CPE Workshop 3 EHRs, Meaningful Use, and Addiction Medicine Carl Christensen, MD, PhD, FASAM Workshop 4 Focus on Curriculum: Building Successful Rotations and Didactics in Addiction Medicine Training Abigail Herron, DO; Petros Levounis, MD, MA, FASAM; Timothy Brennan, MD, MPH; Robbie Bahl, MD Group II - Paper Sessions Paper 6 – Addictions Training During Medical Toxicology Fellowship Timothy Wiegand, MD, FACMT Paper 7 – An Evidence-Based Toolset to Capture, Measure, Analyze & Assess Emotional Health Edward Hill, BCompSc, MCompSc, PhD; Charles Moehs, MD, PhD, MPH; Pierre Dumouchel, MEng, MSc, PhD Paper 8 – Prescription Opioid Abuse – Review of the ACMT Toxicology Investigators Consortium (ToxIC) Case Registry Timothy Wiegand, MD, FACMT Paper 9 – Stroop Performance in Polysubstance Abusers, Pathological Gamblers and Controls Pinhas Dannon, MD; Anat Aizer, MD Paper 10 – Systematic Review: Managing Aberrant Drug Behavior in Primary Care Charles Argoff, MD; Lynn Wilson, MD, CCFP, FCFP; Meldon Kahan, MD, CCFP, FCFP, FRCP(C); Edward Sellers, MD, PhD, FRCPC, FACP
  4:30 pm – 6:00 pm	Networking Reception in the Exhibit Hall  NEW
  6:00 pm	Exhibit Hall Closes
  6:30 pm – 8:30 pm	Ruth Fox Donors Reception (by Invitation Only)
  10:00 pm – 11:00 pm	Mutual Help Meeting

   

   

  Back to top

• Saturday, April 27, 2013

   

  7:00 am – 8:00 am	Mutual Help Meeting
  7:00 am – 5:00 pm	Registration Open
  7:00 am – 8:00 am	Continental Breakfast in the Foyer
  8:00 am – 9:30 am	Policy Plenary Session “US Drug Crisis—The Addiction Treatment Gap.” Keynote: H. Westley Clark, MD, JD, MPH, CAS, FASAM Panelists: Scott Teitelbaum, MD, FAAP, FASAM; Mark Kraus, MD,FASAM; Kelly Clark, MD, MBA, DFAPA, FASAM; Stuart Gitlow, MD, MPH, MBA, FAPA; Michael Miller, MD, FASAM; Robert DuPont, MD, FASAM The Substance Abuse and Mental Health Services Administration (SAMHSA) reports that over 20 million Americans aged 12 and older were classified with substance dependence or abuse in the last year and nearly 17 million Americans were classified with alcohol dependence or abuse. Barely four million received treatment. The gap between need and treatment is wide and it is not improving. H. Westley Clark, MD, JD, MPH, CAS, FASAM will explore the Administration’s efforts to address the addiction treatment gap in this country and the ways that physicians can work with federal partners like SAMHSA to expand access to treatment. Dr. Clark and a panel of policy experts will also discuss the addiction treatment workforce, particularly in light of the expansion of benefits under the Affordable Care Act. As Director of the Center for Substance Abuse Treatment at SAMHSA, Dr. Clark leads the agency’s national effort to provide effective and accessible treatment to all Americans with addictive disorders. Dr. Clark is a noted author and educator in substance abuse treatment, anger and pain management, psychopharmacology, and medical and legal issues. ASAM’s Annual Public Policy Plenary explores federal and state public policies that affect the research, education, prevention and treatment efforts of addiction medicine practitioners. Attendees will gain a more intimate understanding of the practical implications of these policies on their work and on the lives of their colleagues, patients, and students.
  9:30 am – 12:00 pm	Exhibit Hall Open
  9:30 am – 10:00 am	Refreshment Break in the Exhibit Hall
  10:00 am – 12:00 pm	Symposium 4 – Part I AA and Twelve-Step Recovery: New Findings for the Clinician Sponsored by: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Organizers: Marc Galanter, MD, FASAM; Joan Zweben, PhD Marc Galanter, MD, FASAM; Joan Zweben, PhD; Lee Kaskutas, PhD; John Kelly, PhD Because alcohol dependence is a chronic illness subject to relapse after initial treatment, the availability of AA as an adjunct to professional care and as a subsequent support for the patient, provides a valuable resource for many patients. This session, the first of two symposia on mutual help groups, will focus on understanding the way AA can be employed to support sustained recovery. The means by which AA can be successfully integrated into the treatment setting will be explored as well as how this can be undertaken in diverse treatment settings. Examination of recent findings on the character of long-term AA members illustrates how alcoholics in recovery, generally not accessible for study, sustain their abstinence. Finally, an overview on the course of people treated for alcohol and other addictions will be instigated and how AA relates to subsequent abstinence, relapse, and further treatment will be discussed. Symposium 5 Benzodiazepine Use, Misuse, Addiction and Treatment Organizer: Gregory Bunt, MD Gregory Bunt, MD; Christopher Holden, MD; Stephen Ross, MD Benzodiazepines are frequently prescribed by physicians, often including to those with a history of abuse of substances. Longstanding controversies regarding the indication, practice guidelines and outcomes related to prescribing benzodiazepines have not been fully resolved. In the face of the current prescription drug problem nationwide, addiction physicians are advised to revisit this timely and important topic in addiction medicine. Panelist will examine particular clinical challenges, guidelines and case study examples pertinent to prescribing benzodiazepines to individuals with alcoholism and addictive disorders. A review of the research and literature on long-term benzodiazepine prescribing will focus specifically on evidence of long-term efficacy in the treatment of anxiety and insomnia, evidence of development of misuse- and substance-use disorders, and dose escalation. Other problems in long-term prescribing, e.g. cognitive impairment, falls, withdrawal, tolerance will also be reviewed. Furthermore, presentations will explore taper studies after long-term prescribing and different approaches that have been tried and related success rates. Long-term findings after taper--relapse rates, cognitive outcomes, anxiety, and depression outcomes will also be discussed. Symposium 6 Pain Treatment in the Setting of the Prescription Opioid Epidemic Organizer: Mel Pohl, MD, FASAM Mel Pohl, MD, FASAM; Herb Malinoff, MD, FACP, FASAM; Ed Covington, MD; Ross Halpern, PhD More people have died of prescription overdose in the US than from cocaine and heroin combined. The increase in prescriptions for pain medications is clearly associated with the rising problem with the overuse of opioids. As addiction practitioners, we need to become familiar with the facts of the epidemic and methods to intervene with patients and prescribing colleagues. Three lectures by nationally known experts will review the epidemiology of the problem, with a focus on neurobiology, psychology and treatment options that will decrease morbidity and mortality from the excessive prescribing of opioid medications. A panel discussion, including lively audience participation, will explore a variety of critical issues, including: the ability of practitioners to evaluate and manage patients who fail high doses of opioids and sedatives such as those used in hospital management with buprenorphine and other adjunctive medications; to describe the psychosocial components of chronic pain and review the economic aspects of the opioid use and overuse in this epidemic; how to select patients, drugs, and treatment strategies that minimize harm to patients and society. Course 5 Rebuilding Trust: How to Re-integrate When There is Nothing to Put in the Cup James Montgomery, MD; Deborah Corle, PhD; Victor Vines, MD Course 6 Drug Trends: Old Drugs and New Problems; New Drugs and New Problems Jane Maxwell, PhD; Karen Miotto, MD Workshop 5 (Special Interactive Computerized Demo Session) A National Standard for Assessment and Placement: The Open-Source ASAM Criteria Software David Gastfriend, MD; Rodney Conrad, BS; Paul Earley, MD, FASAM Workshop 6 Buprenorphine in Addiction Medicine: Emerging Clinical Issues Robert DuPont, MD, FASAM; Marc Fishman, MD, FASAM; George Kolodner, MD; Eric Wish, PhD
  12:00 pm - 2:00 pm	ASAM Annual Awards Luncheon Price: $65/Per Person Celebrate distinguished leaders in the field of addiction medicine at the Annual ASAM Awards Luncheon. This plated luncheon is an opportunity to network with colleagues, draw inspiration from outstanding accomplishments and welcome new Diplomates, who have successfully passed the ABAM Examination of Certification in Addiction Medicine. Nora D. Volkow, MD, recipient of the John P. McGovern Award, will address the gathering with the Lecture on Addiction and Society. The John P. McGovern MD Award and Lecture on Addiction and Society was established in 1997 to recognize and honor an individual who has made highly meritorious contributions to public policy, treatment, research, or prevention which has increased our understanding of the relationship of addiction and society. The Award is sponsored by an endowment from the John P. McGovern Foundation. Dr. Volkow, became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. Her work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs. Her studies have documented changes in the dopamine system affecting, among others, the functions of frontal brain regions involved with motivation, drive, and pleasure in addiction. She has also made important contributions to the neurobiology of obesity, ADHD, and aging.
  	Additional Award Recipients: The R. Brinkley Smithers Distinguished Scientist Lecture Award Joseph Westermeyer, MD, MPH, PhD Public Policy Award H. Westley Clark, MD, JD, MPH, CAS, FASAM “For outstanding contribution in advancing addiction treatment policy” ASAM Media Award (To Be Announced) “For media that highlights the science, treatment, prevention, and politics of addiction” Medical-Scientific Program Committee Award Timothy Wiegand, MD Paper: “Addiction Training During Medical Toxicology Fellowship” “For the abstract receiving the highest rating for its scientific merit” Young Investigator Award Kay Russos-Ross, MD Paper: “Increasing Trends in Neo-Natal Abstinence Syndrome, What is the Cost?" For the best abstract submitted by an author who is within five years receipt of a doctoral degree” Annual Award Mike Miller, MD, FASAM “For outstanding contributions to the growth and vitality of our Society, for thoughtful leadership in the field, and for deep understanding of the art and science of addiction medicine” Annual Award Carlton Erickson, PhD “For expanding the frontiers of the field of addiction medicine and broadening our understanding of the addiction process, through research and innovation”
  	Recognition of New ABAM Diplomates On December 15, 2012, a record number of over 850 individuals sat for the bi-annual ABAM Certification Examination. At this year’s Annual Awards Luncheon successful candidates, who passed the examination for Certification will be named and recognized as they officially become ABAM Diplomates. The ASAM Awards Luncheon is an ticketed event. Tickets for the luncheon are available for $65 per person. Please use the Registration Form to sign up for this event. Exhibit Hall Closed during the 2013 ASAM Awards Luncheon
  2:00 pm – 4:30 pm	Exhibit Hall Reopens Exhibits officially close at 4:30 pm for the 2013 Med-Sci Conference
  2:00 pm – 4:00 pm	Symposium 4 – Part II Special Clinical Situations for Application with Twelve-Step Programs Sponsored by: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Organizers: Marc Galanter, MD, FASAM; Joan Zweben, PhD Marc Galanter, MD, FASAM; Joan Zweben, PhD; Lee Kaskutas, PhD; John Kelly, PhD Twelve-Step programs can be valuable in aiding substance-dependent patients. However, AA “traditions,” i.e., their governing principles, indicate that they do not affiliate with outside organizations or professionals. In one respect, this has contributed to their success and sustainability, as they can maximally benefit from peer to peer support. On the other hand, this often contributes to difficulty in employing these mutual help groups in relation to treatment. This symposium will present findings on ways in which the clinician can maximize the potential benefit of AA while allowing for its autonomous role. Presenters will describe how Twelve-Step Facilitation, a modality originally developed for individual psychotherapy, can be implemented in a group setting to help patients address the difficulties encountered in their initial engagement in AA. In addition, the highly prevalent problem of combined substance use disorders and general psychiatric illness will be examined, focusing on how mutual help groups can be employed for addressing the particular problems of these dually compromised patients. Finally, the use of AA for adolescent substance abuse (now highly prevalent) will be described, relative to ongoing treatment. Symposium 7 Hepatitis C in 2013: Where are We, Who Should We Treat and With What Should We Treat? Organizers: Michael Fingerhood, MD; Alfonso Paredes, MD Michael Fingerhood, MD; Alfonso Paredes, MD; Sanjeev Arora, MD; Andrew Talal, MD, MPH It is estimated that 3.5 million persons in the US are infected with the Hepatitis C (HCV) virus. This serious disease accounts for 10,000 deaths annually in the United States alone. The disorder has been called a silent epidemic because it does not have the public visibility proportional to its seriousness and prevalence. Injection drug use is the major risk factor for HCV in the United States. In several cohort studies of injection drug users, as many as 90% of individuals are infected with HCV. The treatment of HCV, however, has evolved over the past five years. While treatment of HCV may not be within the scope of practice of most physicians dedicated to the treatment of addiction, knowledge of screening, testing, prevention and treatment modalities is imperative. Presentations will share knowledge of hepatitis C virology, the epidemiology of the virus, and understanding of hepatitis C progression in individuals, including data from a Johns Hopkins cohort, looking at 20 year mortality data for a cohort of 450 patients who sought treatment for substance abuse on an inpatient CDU in 1990-91. In addition, the session will explore current hepatitis C treatment modalities and what is on the horizon, including an understanding of what is involved in treatment and selection of patients to be treated. Finally, participants will learn about the ECHO model--a method that offers training, advice and support to primary care providers from underserved areas--for delivering best practice care for patients with complex health complex conditions such as hepatitis C. Course 7 Implementing Overdose Death Prevention Programs with Naloxone Sharon Stancliff, MD; Alexander Walley, MD Course 8 Co-Occurring Addiction and Chronic Pain: Evidence Based Strategies for Recovery Seddon Savage, MD, MS, FASAM; Robert Jamison, PhD; Steven Colameco, MD, MEd, FASAM; Robert Edwards, PhD Workshop 5 (Special Interactive Computerized Demo Session) A National Standard for Assessment and Placement: The Open-Source ASAM Criteria Software David Gastfriend, MD; Rodney Conrad, BS; Paul Earley, MD, FASAM Component Session 7 Women and Substance Use Disorders - An Action Group Update Catherine Friedman, MD; Jacquelyn Starer, MD, FACOG, FASAM Component Session 8 Adolescent Action Group: Addressing Emotion Regulation in Adolescent Treatment Organizer:  Marc Fishman, MD Marc Fishman, MD; Hoa Vo, PhD; Carisa Perry-Parrish, PhD; Shonal Saha, MD
  4:00 pm – 4:30 pm	Refreshment Break in the Exhibit Hall Last chance to see Exhibitors
  4:30 pm	2013 Exhibit Hall Closes
  4:30 pm – 6:30 pm	Symposium 8 Addressing Care for Hepatitis C Virus Infection in the Addicted Patient: The Dawn of a New Era in Screening and Treatment Sponsored by: National Institute on Drug Abuse (NIDA) Organizer: Jag Khalsa, PhD, MS Jag Khalsa, PhD, MS; Jeffrey Samet, MD, MA, MPH; Alain Litwin, MD, MPH; Lynn Taylor, MD, AAHIVS, FACP; Jutith Tsui, MD, MPH Hepatitis C virus (HCV) infection is highly prevalent among substance users, but numerous studies demonstrate substantial barriers to care among drug users. The current model for delivery of care (specialist referral) cannot encompass the sheer numbers of patients infected, nor does it address the special needs of patients with drug addiction.   New models of systems of delivery of care that integrate HCV care with substance use treatment are needed to reduce barriers and enable addicted patients to access needed treatments. This issue is particularly timely, as new guidelines will inevitably identify greater numbers of patients who are infected (and who still struggle with addictions). Better treatments are currently available (or soon to become available), which will tip the decisional balance in favor of treating patients with past or current addictions. Presentations will introduce providers to the available new treatment modalities such as integrated care models, recent developments in screening guidelines and pharmacotherapy options that have the potential to improve health outcomes among HCV-infected patients with addictions. Dr. Alain Litwin will review the scope of the problem and the rationale for providing integrated care for HCV, Dr. Lynn Taylor will describe/discuss examples of new models of integrated care for HCV for patients with addictions, Dr. Judy Tsui will discuss new developments in HCV screening recommendations and opportunities for brief interventions and discuss implications for expanding treatment for patients with addictions. Finally, Dr. Khalsa will discuss the funding opportunities at NIH. Symposium 9 Meeting the Needs of Veterans in the Community Organizer: Joan Zweben, PhD Jeff Goldsmith, MD, FASAM; John Straznikas, MD; Kristine Burkman, PhD Many veterans seek help in community programs, where the unique needs of the military culture are not fully appreciated or understood by program staff. Presenters will explore key assessment and treatment issues to enhance providers' ability to meet patient needs. Participants will explore the distinctive needs of veterans and as a consequence offer more effective treatment. Presented through lecture, with some time for questions regarding military culture, PTSD/TBI, and resources currently available, speakers will describe unique features of military culture that affect engagement and participation in treatment. Participants will learn to describe key issues and recommended interventions for patients with PTSD and TBI and to identify VA resources potentially available and describe how to access them. Course 9 Using Family Interaction Mapping to Identify Hidden Benefits of Substance Abuse Relapse Michael Liepman, MD; Kathleen Gross, MD Workshop 5 (Special Interactive Computerized Demo Session) A National Standard for Assessment and Placement: The Open-Source ASAM Criteria Software David Gastfriend, MD; Rodney Conrad, BS; Paul Earley, MD, FASAM Workshop 7 Treatment of Substance Use Disorders in the Criminal Justice System Frank Vocci, PhD; Robert Schwartz, MD; Terrence Fitzgerald, MD Workshop 8 Program Experiences in the Development of an Accredited Addiction Medicine Residency, the National Addiction Medicine Residency Assistance Council, and Recognition of Addiction Medicine as a Medical Specialty by the American Board of Medical Specialties (ABMS). Jeffrey Samet, MD, MA, MPH; Petros Levounis, MD, MA, FASAM; Scott Teitelbaum, MD, FACP, FASAM; Patric O’Connor, MD,MPH, FACP; David Withers, MD
  5:00 pm – 6:00 pm	Ruth Fox Endowment Scholarship Meeting
  10:00 pm – 11:00 pm	Mutual Help Meeting

   

  Back to top

• Sunday, April 28, 2013

   

  7:00 am – 8:00 am	Mutual Help Meeting
  7:00 am – 12:00 pm	Registration Open
  7:00 am – 8:00 am	Continental Breakfast in the Foyer
  8:00 am – 10:00 am	Group III - Paper Sessions Paper 11 – A Comparison of AMA Rates of 5 Opioid Detoxification Protocols Cynthia Brown, BA, MD Paper 12 – Emerging Adults Vanish from Buprenorphine Treatment Zev Schuman-Olivier, MD Paper 13 – Integrated Substance Abuse Treatment: Buprenorphine in a Primary Care Clinic Genie Bailey, MD; Nancy Paull, MS; Michael Stein, MD Paper 14 – Opioid Treatment at Release from Jail Using Extended-Release Naltrexone Joshua Lee, MD, MS Paper 15 – Primary Care Patient Characteristics Associated with Completion of 6-month Buprenorphine Treatment Anne Neumann, PhD, MA; Richard Blondell, MD; Mohammadreza Azadfard, MD Symposium 10 The Addiction Medicine/Primary Care Interface: Models of Integrated Care Organizer: Judith Martin, MD, FASAM; Jag Khalsa, PhD, MS Sharon Abramowitz, MD; Daniel Alford, MD, MPH, FASAM, FACP; Judith Martin, MD, FASAM Through first-hand experience navigating the addiction-primary care interface, three noted addiction physicians will highlight integrated models of care that work. Dr. Sharon Abramowitz will share the core lessons learned after over twenty years of being the only consult-liaison/addiction psychiatrist member of an urban county hospital internal medicine department and core faculty member of a primary care residency. Through specific case examples, Dr. Abramowitz will describe how addiction medicine specialists can upgrade the addiction medicine skills of our primary care colleagues through direct teaching, consultation, modeling and empathy with their clinical challenges. Dr. Alford will review current "standards of care" for the safe use of opioids in treating chronic pain including use of risk assessment and monitoring tools. He will present an update on evidence-based primary care-based models of care described in the literature. Using a case-based approach, Dr. Alford will describe a multidisciplinary model that is currently under development at Boston Medical Center. Patients are present in the OTP daily or weekly, making it an ideal location to offer full mental health and primary care services for homeless and disabled patients. Dr. Judith Martin will discuss the challenges and benefits of integration, including health coaching by drug counselors, medication monitoring by dispensing nurses, and use of addiction-related quality markers in primary care reporting. Workshop 9 Recovery-Oriented Treatment for Nicotine Dependence Terry Rustin, MD, FASAM Workshop 10 Substance Abuse and Post-Traumatic Stress Disorder (PTSD): Chicken first or an Egg? Guifang Lao, MD, PhD; Charles Marmar, MD; Shwe Gyaw, MD
  10:00 am – 10:15 am	Refreshment Break in the Foyer
  10:15 am – 12:15 pm	Symposium 11 International Perspectives on Addiction Medicine Co-sponsored by the International Society of Addiction Medicine (ISAM) and the National Institute on Drug Abuse (NIDA) Organizer: Marc Galanter, MD, FASAM Marc Galanter, MD, FASAM; Petros Levounis, MD, MA, FASAM; Jag Khalsa, PhD, MS; George Woody, MD; Brian Hurley, MD; Thor Tyrfingsson, MD International clinical research on substance use disorders has seen remarkable growth in recent years. While some of this growth can be attributed to new modalities of treatment for the very same problems and disorders confronting American clinicians in the addiction field, other research studies are investigating problems different from our own, yet still ones that shed light on the issues confronted in the American treatment community. The membership of the International Society of Addiction Medicine (ISAM), established in 1998, includes a large, worldwide representation of addiction specialists who have regularly met to present and exchange their respective findings. ASAM, in conjunction with NIDA, will present findings from global clinical researchers and their clinically-applicable experiences that shed light on the problems we confront here in the United States. These presentations illustrate how we can broaden and extend our competency in addiction treatment and research by leveraging the unique experience drawn from the international arena. Participants will explore innovative aspects of clinical addiction medicine from an international perspective and discover the role of NIDA and ISAM in addiction care and research. As a result, they will become better able to provide and organize care for addicted patients. Workshop 11 Improving Addiction Care in Primary Care Norman Wetterau, MD, FASAM; Bruce Maslack Workshop 12 How to Talk So Patients will Listen and How to Listen so Patients will Talk: A Motivational Interviewing Primer Peter Selby, MBBS, CCFP, FCFP Component Session 9 ABAM Certification and Preparation for the Cognitive Examination Kevin Kunz, MD, MPH, FASAM; Michael Weaver, MD, FASAM; Lon Hays, MD, MBA, DFAPA